VaxGen Phase III AIDS Vaccine Trial

Tuesday, 25 February 2003, 8:20 am | VaxGen

VaxGen, Inc. (Nasdaq: VXGN) today announced initial results from the first of its three-year, multi-national, randomized, double-blind, placebo-controlled Phase III trials of AIDSVAX (rgp120) to prevent HIV infection. More >>